In hepatocellular carcinoma, RND1 depletion with siRNA induces the resistance of hepatocellular carcinoma cells to cisplatin, a water-soluble platinum complex [45], whereas RND1 re-expression induced by cell treatment with an inducer of promoter hypomethylation and an histone deacetylase inhibitor increases the cellular sensitivity to the Raf inhibitor, sorafenib [46]. The gene discussed is RND1; the disease is hepatocellular carcinoma.